A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
In this episode, we are featuring Kiora Pharmaceuticals (Nasdaq: KPRX), a clinical-stage biotechnology company developing advanced therapies for retinal disease. This interview is moderated by Robert Blum, Managing Partner at Lytham Partners, and features Brian Strem,...
During this presentation we welcome, Kiora Pharmaceuticals. Kiora (Nasdaq: KPRX) is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. This Company Webcast was recorded during the Lytham...
During this presentation and webcast, we welcome Kiora Pharmaceuticals, ticker symbol of KPRX on the NASDAQ. And joining us today from the company is Brian Strem. Brian is the company’s Chief Executive Officer, and we also have Melissa Tosca, the company’s EVP of...
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a...